Home Ad Exchange News Recount Surprise: Marc Pritchard’s Agenda Under Siege As Activist Peltz Appears To Win P&G Board Seat

Recount Surprise: Marc Pritchard’s Agenda Under Siege As Activist Peltz Appears To Win P&G Board Seat

SHARE:

Activist investor Nelson Peltz of Trian Fund Management won a recount vote for a board seat at Procter & Gamble.

In the wake of the early October vote, the initial vote count had Peltz down by a narrow margin, but that now appears to be wrong. In a statement shared with AdExchanger late Wednesday, the company said Peltz “is leading” by a tiny margin of 0.0016% of shareholder votes. P&G will still be able to challenge Wednesday’s recount during a review period.

Peltz would hold only one of 11 board seats, and has previously said he would support expanding the board to 12 to re-seat Ernesto Zedillo, Peltz’s opponent in his board vote (and the former president of Mexico), but the reversal could have repercussions in how the world’s biggest ad spender approaches marketing.

In its report supporting Peltz’s bid, Trian advocated for P&G to consolidate from 10 brand categories to three – “beauty, grooming and health care,” “fabric and home care” and “baby, feminine and family care” – and to reinvest savings from cutbacks.

Trian is not only interested in short-term profit gains. In P&G’s earnings report in July, CFO Jon Moeller said the company had trimmed $140 million from its cost structure, most of it from digital advertising.

P&G’s drop in ad spend helped preserve strong profit margins despite tepid sales, but, according to the Trian report, those gains should have gone to “other forms of brand-building to regain lost market share. Instead, management chose not to reinvest, in our view benefitting near-term earnings at the expense of long-term growth.”

It remains to be seen how Peltz’s potential board entrance will affect P&G’s advertising or Marc Pritchard, the company’s chief Brand Officer and one of the most vocal brand executives on transparency issues in digital media.

“It doesn’t matter about me. What really matters is the employees of P&G, the community in which we operate and the shareholders,” Pritchard told AdExchanger in October, the week before stockholders voted, about the Trian move.

“Splitting the company into three is a very bad idea,” he said. “We’ve done a lot of analysis that indicates that it would add a lot more cost to the business.”

Must Read

Rest In Privacy, Sandbox

Last week, after nearly six years of development and delays, Google officially retired its Privacy Sandbox.
Which means it’s time for a memorial service.

AWS Launches A Cloud Infrastructure Service For Ad Tech

AWS RTB Fabric offers ad tech platforms more streamlined integrations with ecosystem and infrastructure partners, allegedly lower latency compared to the public internet and discounts on data transfers.

Netflix Boasts Its Best Ad Sales Quarter Ever (Again)

In a livestreamed presentation to investors on Tuesday, co-CEO Greg Peters shared that Netflix had its “best ad sales quarter ever” in Q3, and more than doubled its upfront commitments for this year.

Privacy! Commerce! Connected TV! Read all about it. Subscribe to AdExchanger Newsletters
Comic: No One To Play With

Google Pulls The Plug On Topics, PAAPI And Other Major Privacy Sandbox APIs (As The CMA Says ‘Cheerio’)

Google’s aborted cookie crackdown ends with a quiet CMA sign-off and a sweeping phaseout of Privacy Sandbox technologies, from the Topics API to PAAPI.

The Trade Desk’s Auction Evolutions Bring High Drama To The Prebid Summit

TTD shared new details about OpenAds features that let publishers see for themselves whether it’s running a fair auction. But tension between TTD and Prebid hung over the event.

Monopoly Man looks on at the DOJ vs. Google ad tech antitrust trial (comic).

How Google Stands In The DOJ’s Ad Tech Antitrust Suit, According To Those Who Tracked The Trial

The remedies phase of the Google antitrust trial concluded last week. And after 11 days in the courtroom, there is a clearer sense of where Judge Leonie Brinkema is focused on, and how that might influence what remedies she put in place.